Abstract:Discovery and development of new molecules directed against validated pain targets is required to advance the treatment of pain disorders. Voltage-gated sodium channels (Na V s) are responsible for action potential initiation and transmission of pain signals. Na V 1.8 is specifically expressed in peripheral nociceptors and has been genetically and pharmacologically validated as a human pain target. Selective inhibition of Na V 1.8 can ameliorate pain while minimizing effects on other Na V isoforms essential for cardiac, respiratory, and central nervous system physiology. Here we present the pharmacology, interaction site, and mechanism of action of LTGO-33, a novel Na V 1.8 small molecule inhibitor. LTGO-33 inhibited Na V 1.8 in the nM potency range and exhibited over 600-fold selectivity against human Na V 1.1–Na V 1.7 and Na V 1.9. Unlike prior reported Na V 1.8 inhibitors that preferentially interacted with an inactivated state via the pore region, LTGO-33 was state-independent with similar potencies against closed and inactivated channels. LTGO-33 displayed species specificity for primate Na V 1.8 over dog and rodent Na V 1.8 and inhibited action potential firing in human dorsal root ganglia neurons. Using chimeras combined with mutagenesis, the extracellular cleft of the second voltage-sensing domain was identified as the key site required for channel inhibition. Biophysical mechanism of action studies demonstrated that LTGO-33 inhibition was relieved by membrane depolarization, suggesting the molecule stabilized the deactivated state to prevent channel opening. LTGO-33 equally inhibited wild-type and multiple Na V 1.8 variants associated with human pain disorders. These collective results illustrate LTGO-33 inhibition via both a novel interaction site and mechanism of action previously undescribed in Na V 1.8 small molecule pharmacologic space. SIGNIFICANCE STATEMENT Na V 1.8 sodium channels primarily expressed in peripheral pain-sensing neurons represent a validated target for the development of novel analgesics. Here we present the selective small molecule Na V 1.8 inhibitor LTGO-33 that interdicts a distinct site in a voltage-sensor domain to inhibit channel opening. These results inform the development of new analgesics for pain disorders.

ST‐2560, a selective inhibitor of the NaV1.7 sodium channel, affects nocifensive and cardiovascular reflexes in non‐human primates

Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies That Target Nav1.7 : Differential Activities of Nav1.7-targeting Monoclonal Antibodies.

Small Interfering RNA-mediated Selective Knockdown of NaV1.8 Tetrodotoxin-Resistant Sodium Channel Reverses Mechanical Allodynia in Neuropathic Rats

Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7

Analgesia and peripheral c-fiber modulation by selective Nav1.8 inhibition in rhesus

Unique electrophysiological property of a novel Nav1.7, Nav1.8, and Nav1.9 sodium channel blocker, ANP-230

2-Aminopyridines as Potent and Selective Na v 1.8 Inhibitors Exhibiting Efficacy in a Nonhuman Primate Pain Model

Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats

Molecular Pharmacology of Selective Na V 1.6 and Dual Na V 1.6/Na V 1.2 Channel Inhibitors that Suppress Excitatory Neuronal Activity Ex Vivo

A modulator of the low-voltage activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies.

Structural basis for Na V 1.7 inhibition by pore blockers

Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel NaV1.8 with a Unique Mechanism of Action

Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy

Drug discovery targeting Nav1.8: Structural insights and therapeutic potential

Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors

Structural basis for high-voltage activation and subtype-specific inhibition of human Na v 1.8.

Discovery of selective Na V 1.8 inhibitors based on 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain

Structural basis for high-voltage activation and subtype-specific inhibition of human Na<sub>v</sub>1.8

Discovery of Selective NaV1.8 Inhibitors Based on 5-Chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl Nicotinamide Scaffold for the Treatment of Pain

Insights into the voltage-gated sodium channel, NaV1.8, and its role in visceral pain perception

Role of NaV1.7 in postganglionic sympathetic nerve function in human and guinea‐pig arteries